Translate this page into:
ORIGINAL ARTICLE: Lung Cancer
doi:
10.4103/sajc.sajc_30_18
Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey
1
Department of Medical Oncology, Tata Memorial Hosptial, Mumbai
2
Department of Medical Oncology, Asian Institute of Oncology, Mumbai
3
Department of Medical Oncology, Indo American Hospital, Hyderabad, Telangana
4
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
5
Department of Medical Oncology, Shatabdi Hospital, Nasik, Maharashtra
6
Department of Medical Oncology, HCG Hospital, Bengaluru, Karnataka
7
Department of Medical Oncology, Vendant Hospital, Ahmedabad, Gujarat
8
Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana
9
Department of Oncology/Respiratory Medical Affairs Boehringer Ingelheim India Pvt. Ltd., Mumbai
10
Department of Medical Oncology, Sparsh Hospital, Bhubaneswar, Odisha
11
Department of Medical Oncology, Chirayu Hospital, Bhopal, Madhya Pradesh
12
Department of Medical Oncology, Tata Medical Centre
13
Department of Medical Oncology, Narayana Superspeciality Hospital, Kolkata, West Bengal
14
Department of Medical Oncology, Apollo Hospitals, New Delhi
15
Department of Medical Oncology, Medanta - The Medicity, Gurugram, Haryana, India
16
Department of Medical Oncology, RGCI, New Delhi
*Corresponding author: Dr. Kumar Prabhash. kprabhash1@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
The resounding success of imatinib (IM) as front line treatment in patients with chronic myeloid leukemia (CML) has certainly made a paradigm shift in the therapeutic algorithm of this disorder. The precise targeting of the BCR-ABL oncogene in CML has entitled it to be the poster child of translational medicine with a well-deserved Oscar ovation from the oncology community. Clinicians are now empowered with first-, second- and third-generation tyrosine kinases, as well as advanced molecular tools to monitor disease and characterize resistance. We have come a long way in successfully managing these patients, but there are still a significant few unmet clinical needs which need addressing and targeting to optimize clinical outcomes. This review focuses on 4 such pertinent and relevant clinical issues, which still need ironing out to fulfill our ambition of achieving ′perfection′ in this patient cohort.
Keywords
References
- Malik PS, Raina V. Lung cancer: Prevalent trends & emerging concepts. Indian J Med Res 2015;141:5-7.
- Sebastian M, Schmittel A, Reck M. First-line treatment of EGFR-mutated nonsmall cell lung cancer: Critical review on study methodology. Eur Respir Rev 2014;23:92-105.
- Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
- Noronha V, Prabhash K, Thavamani A, Chougule A, Purandare N, Joshi A, et al. EGFR mutations in indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy. PLoS One 2013;8:e61561.
- Veldore VH, Rao RM, Kakara S, Pattanayak S, Tejaswi R, Sahoo R, et al. Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in india. Indian J Cancer 2013;50:87-93.
- Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of indian ethnicity. PLoS One 2013;8:e76164.
- Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from india. Lung Cancer 2011;73:316-9.
- Dey S. India has just 2,000 oncologists for 10 million Patients; 2016. Available from: https://timesofindia.indiatimes.com/india/India-has-just-2000-oncologists-for-10-million-patients/articleshow/50842842.cms. [Last accessed on 2017 Dec15].
- Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
- Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget 2016;7:1066-75.
- Choughule A, Noronha V, Joshi A, Desai S, Jambhekar N, Utture S, et al. Epidermal growth factor receptor mutation subtypes and geographical distribution among indian non-small cell lung cancer patients. Indian J Cancer 2013;50:107-11.
- Joshi A, Zanwar S, Noronha V, Patil VM, Chougule A, Kumar R, et al. EGFR mutation in squamous cell carcinoma of the lung: Does it carry the same connotation as in adenocarcinomas? Onco Targets Ther2 017;10:1859-63.